EVALUATION OF LACTATE DEHYDROGENASE (LDH) AS A MARKER FOR LORLATINIB EFFICACY IN PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC).

被引：0
|
作者：
Dinh, M. [1 ]
Pithavala, Y. [1 ]
Chen, J. [1 ]
机构：
[1] Pfizer, San Diego, CA USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2022年 / 111卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P-053
引用
收藏
页码：S19 / S19
页数：1
相关论文
共 50 条
  • [31] Lorlatinib: a promising drug in the future treatment of advanced ALK-positive non-small-cell lung cancer
    Richter, Johanna
    Dunst, Juergen
    STRAHLENTHERAPIE UND ONKOLOGIE, 2021, 197 (07) : 657 - 660
  • [32] Crizotinib: A targeted therapy in advanced ALK-positive non-small cell lung cancer
    Toffart, A. -C.
    Sakhri, L.
    Moro-Sibilot, D.
    REVUE DE PNEUMOLOGIE CLINIQUE, 2013, 69 (02) : 111 - 116
  • [33] Efficacy of Ceritinib After Alectinib for ALK-positive Non-small Cell Lung Cancer
    Yoshida, Hironori
    Kim, Young Hak
    Ozasa, Hiroaki
    Sakamori, Yuichi
    Tsuji, Takahiro
    Nomizo, Takashi
    Yasuda, Yuto
    Yamamoto, Tomoko
    Ajimizu, Hitomi
    Hirai, Toyohiro
    IN VIVO, 2018, 32 (06): : 1587 - 1590
  • [34] Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial
    Soo, Ross A.
    Tan, Eng Huat
    Hayashi, Hidetoshi
    Seto, Takashi
    Lin, Chia-Chi
    Ou, Sai-Hong Ignatius
    Kim, Dong-Wan
    Liu, Geoffrey
    Abbattista, Antonello
    Martini, Jean-Francois
    Martini, Francois
    Wong, Chew Hooi
    Toffalorio, Francesca
    Solomon, Benjamin J.
    LUNG CANCER, 2022, 169 : 67 - 76
  • [35] Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer
    Shaw, A. T.
    Varghese, A. M.
    Solomon, B. J.
    Costa, D. B.
    Novello, S.
    Mino-Kenudson, M.
    Awad, M. M.
    Engelman, J. A.
    Riely, G. J.
    Monica, V.
    Yeap, B. Y.
    Scagliotti, G. V.
    ANNALS OF ONCOLOGY, 2013, 24 (01) : 59 - 66
  • [36] Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer
    Nishio, Makoto
    Kim, Dong-Wan
    Wu, Yi-Long
    Nakagawa, Kazuhiko
    Solomon, Benjamin J.
    Shaw, Alice T.
    Hashigaki, Satoshi
    Ohki, Emiko
    Usari, Tiziana
    Paolini, Jolanda
    Polli, Anna
    Wilner, Keith D.
    Mok, Tony
    CANCER RESEARCH AND TREATMENT, 2018, 50 (03): : 691 - 700
  • [37] Catechol estrogen profiles of patients with EGFR- and ALK-positive non-small cell lung cancer (NSCLC)
    Bodor, J. Nicholas
    Treat, Joseph
    Krzizike, Daniel D.
    Zawislak, Carolyn L.
    Vanderveer, Lisa
    Eidbo, Sarah
    Ross, Eric A.
    Edelman, Martin J.
    Andrews, Andrew J.
    Clapper, Margie L.
    CANCER RESEARCH, 2022, 82 (12)
  • [38] From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer
    Pirker, Robert
    Filipits, Martin
    ESMO OPEN, 2019, 4 (05)
  • [39] Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC).
    Kim, Dong-Wan
    Ahn, Myung-Ju
    Shi, Yuankai
    De Pas, Tommaso Martino
    Yang, Pan-Chyr
    Riely, Gregory J.
    Crino, Lucio
    Evans, Tracey L.
    Liu, Xiaoqing
    Han, Ji-Youn
    Salgia, Ravi
    Moro-Sibilot, Denis
    Ou, Sai-Hong Ignatius
    Gettinger, Scott N.
    Wu, Yi Long
    Lanzalone, Silvana
    Polli, Anna
    Iyer, Shrividya
    Shaw, Alice Tsang
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [40] Clinical presentation of hepatotoxicity-associated crizotinib in ALK-positive (ALK plus ) advanced non-small cell lung cancer (NSCLC).
    Schnell, Patrick
    Safferman, Allan Zachary
    Bartlett, Cynthia Huang
    Tang, Yiyun
    Wilner, Keith D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345